Cambridge Research Biochemicals to provide monoclonal antibody production
UK-based Cambridge Research Biochemicals (CRB), a specialist in the custom production of polyclonal antibodies, is expanding its antibody offering to include monoclonal antibody production via two new agreements with Babraham Bioscience Technologies (BBT) and US company Epitomics.
UK-based Cambridge Research Biochemicals (CRB), a specialist in the custom production of polyclonal antibodies, is expanding its antibody offering to include monoclonal antibody production via two new agreements with Babraham Bioscience Technologies (BBT) and US company Epitomics.
CRB and BBT, of Cambridge in the UK, have formed an alliance that will enable CRB to market custom monoclonal antibody projects (via mouse/rat hybridomas) from BBT. The deal will combine CRB capability in peptide synthesis for antigen use and the mAb production skills of BBT, and will considerably enhance CRB's suite of offerings, as well as allowing BBT to open up its route to market.
In addition, CRB has established a relationship with Epitomics that will enable CRB's rabbit polyclonal antibody projects to be transferred to Epitomics" rabbit monoclonal antibody (RabMAbs) projects. The resulting combined service will enable both commercial and non-commercial organisations to access the unique RabMAbs technology for research, diagnostics and therapeutics.
"CRB is continuing to grow and develop, and these latest joint ventures further strengthen our position in the industry," said Emily Humphrys, CRB's commercial director. "We believe our partnerships can make a real difference to drug discovery."